TNFRSF6B and neoplasm: If similar to armored CAR-T cells [51], which overcome the barrier of adverse tumor microenvironment by constitutively releasing inflammatory cytokines such as IL-12 (or armed to secrete other cytokines), engineered CAR-T cell capable of blocking the function of amplified decoy Fas receptors [52] (such as DCR3, etc.)in the heterogeneous tumor microenvironment to maintain superior bystander function is also an exciting area of investigation.